Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
Public ClinicalTrials.gov record NCT00591266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.
Study identification
- NCT ID
- NCT00591266
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 566 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2007 (Type not available)
- Primary completion
- Mar 2009 (Actual)
- Completion
- Apr 2009 (Actual)
- Last update posted
- Jul 22, 2011
2007 – 2009
United States locations
- U.S. sites
- 50
- U.S. states
- 24
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mesa | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | Burbank | California | — | — |
| Not listed | Burlingame | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Roseville | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Wheat Ridge | Colorado | — | — |
| Not listed | Newark | Delaware | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Longwood | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Gurnee | Illinois | — | — |
| Not listed | Peoria | Illinois | — | — |
| Not listed | Elkhart | Indiana | — | — |
| Not listed | Crestview Hills | Kentucky | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Riverdale | Maryland | — | — |
| Not listed | Brockton | Massachusetts | — | — |
| Not listed | Haverhill | Massachusetts | — | — |
| Not listed | North Dartmouth | Massachusetts | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Canton | Ohio | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Mogadore | Ohio | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Warminster | Pennsylvania | — | — |
| Not listed | Cumberland | Rhode Island | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Irvine | Texas | — | — |
| Not listed | Lake Jackson | Texas | — | — |
| Not listed | North Richland Hills | Texas | — | — |
| Not listed | Manassas | Virginia | — | — |
| Not listed | Renton | Washington | — | — |
| Not listed | Menomonee Falls | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00591266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2011 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00591266 live on ClinicalTrials.gov.